Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMYTCVE:BMKNASDAQ:FIRETSE:HLSNYSEAMERICAN:ZOM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMYTAmryt Pharma$14.70+0.1%$14.64$6.41▼$14.77$940.21M0.84757,360 shs2.39 million shsBMKMacDonald Mines ExplorationC$0.09-10.5%C$0.08C$0.03▼C$0.10C$3.24M0.1567,505 shs26,780 shsFIRE(FIRE)$0.00$0.00▼$0.00N/AN/AN/AN/AHLSHLS TherapeuticsC$4.94+0.8%C$4.78C$3.00▼C$5.23C$109.90M1.0713,547 shs6,301 shsZOMZomedica$0.12$0.09▼$0.17$95.35M1.034.56 million shs790,936 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMYTAmryt Pharma0.00%0.00%0.00%0.00%0.00%BMKMacDonald Mines Exploration0.00%0.00%0.00%0.00%+112.50%FIRE(FIRE)0.00%0.00%0.00%0.00%0.00%HLSHLS Therapeutics0.00%+3.13%+0.41%+19.04%+35.71%ZOMZomedica0.00%0.00%0.00%0.00%-32.76%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMYTAmryt PharmaN/AN/AN/AN/AN/AN/AN/AN/ABMKMacDonald Mines ExplorationN/AN/AN/AN/AN/AN/AN/AN/AFIRE(FIRE)N/AN/AN/AN/AN/AN/AN/AN/AHLSHLS Therapeutics0.4389 of 5 stars1.00.01.70.00.03.30.0ZOMZomedicaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMYTAmryt Pharma 0.00N/AN/AN/ABMKMacDonald Mines Exploration 0.00N/AN/AN/AFIRE(FIRE) 0.00N/AN/AN/AHLSHLS Therapeutics 2.00HoldC$4.50-8.91% DownsideZOMZomedica 4.00Strong BuyN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMYTAmryt Pharma$222.54M4.22$0.98 per share14.98$5.58 per share2.63BMKMacDonald Mines Exploration-C$74K-43.74C$0.01 per share13.00C($0.02) per share-4.25FIRE(FIRE)N/AN/AN/AN/AN/AN/AHLSHLS TherapeuticsC$40.13M2.74C$0.32 per share15.22C$2.51 per share1.97ZOMZomedica$25.19M0.00N/AN/A$0.24 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMYTAmryt Pharma$1M-$0.06N/A735.00N/A-8.19%1.70%0.75%N/ABMKMacDonald Mines Exploration-C$1.28MN/AN/A∞N/AN/A-1,679.48%-118.05%N/AFIRE(FIRE)N/AN/A0.00N/AN/AN/AN/AN/AN/AHLSHLS Therapeutics-C$15.53M-C$1.00N/A∞N/A-38.70%-25.27%-2.89%N/AZOMZomedica-$34.53M-$0.06N/AN/AN/A-232.88%-12.47%-11.84%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMYTAmryt PharmaN/AN/AN/AN/AN/ABMKMacDonald Mines ExplorationN/A1.24%N/AN/AN/AFIRE(FIRE)N/AN/AN/AN/AN/AHLSHLS TherapeuticsC$0.204.05%N/AN/A N/AZOMZomedicaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMYTAmryt Pharma0.641.570.94BMKMacDonald Mines Exploration3.840.100.27FIRE(FIRE)N/AN/AN/AHLSHLS Therapeutics86.501.561.01ZOMZomedicaN/A10.8210.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMYTAmryt Pharma71.31%BMKMacDonald Mines ExplorationN/AFIRE(FIRE)N/AHLSHLS Therapeutics65.20%ZOMZomedica8.95%Insider OwnershipCompanyInsider OwnershipAMYTAmryt Pharma5.66%BMKMacDonald Mines Exploration6.86%FIRE(FIRE)N/AHLSHLS Therapeutics0.37%ZOMZomedica4.19%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMYTAmryt Pharma2,02063.96 million60.34 millionNot OptionableBMKMacDonald Mines Exploration238.08 millionN/ANot OptionableFIRE(FIRE)N/AN/AN/ANot OptionableHLSHLS Therapeutics9122.25 millionN/ANot OptionableZOMZomedica50979.95 million938.89 millionNot OptionableBMK, ZOM, AMYT, FIRE, and HLS HeadlinesRecent News About These CompaniesZomedica Announces Issuance of Additional Patent for its TRUVIEW (R) Microscope - MorningstarJune 25, 2025 | morningstar.comMZomedica Corp.: Zomedica Unveils Exclusive Fourth Friday at Four Webinar Series to Explore Cutting-Edge Veterinary InnovationsMay 20, 2025 | finanznachrichten.deTreat pet pain, inflammation, and anxiety with this high-tech at home therapyApril 24, 2025 | click2houston.comCHelping Pets Live Pain-Free: High-Tech Treatments for Our Four-Legged Family MembersApril 11, 2025 | pix11.comPIs Zomedica Corp. (ZOMDF) the Cheapest Stock Insiders Are Buying In March?March 28, 2025 | insidermonkey.com15 Cheapest Stocks Insiders Are Buying In MarchMarch 27, 2025 | insidermonkey.comEarnings call transcript: Zomedica Q4 2024 shows revenue growthMarch 15, 2025 | investing.comQ4 2024 Zomedica Corp Earnings CallMarch 15, 2025 | finance.yahoo.comZomedica Corp. (ZOMDF) Q4 2024 Earnings Call TranscriptMarch 13, 2025 | seekingalpha.comZomedica (ZOMDF) Gets a Buy from Noble FinancialMarch 11, 2025 | markets.businessinsider.comZomedica Corp.March 8, 2025 | wsj.comZomedica Corp. Announces Transition to OTCQB Venture MarketMarch 4, 2025 | accessnewswire.comANYSE American to Commence Delisting Proceedings Against Zomedica Corp. (ZOM)March 4, 2025 | businesswire.comZomedica to Report Fourth Quarter and Full Year 2024 Financial Results with a Business Update on March 13th at 4:30 p.m. ETFebruary 26, 2025 | accessnewswire.comAZomedica Corp.: Zomedica Improves Efficiency and Cuts Costs by Moving to New HeadquartersFebruary 12, 2025 | finanznachrichten.deZomedica Improves Efficiency and Cuts Costs by Moving to New HeadquartersFebruary 12, 2025 | accessnewswire.comAZomedica Corp.: Zomedica Launches the TRUFORMA Enhanced Endogenous ACTH Assay to aid in Equine PPID DiagnosisFebruary 6, 2025 | finanznachrichten.deZomedica Launches the TRUFORMA(R) Enhanced Endogenous ACTH Assay to aid in Equine PPID DiagnosisFebruary 6, 2025 | accessnewswire.comAZomedica Corp (ZOM) Stock Sees Market Value Hit $118.58 million: What Are the Implications?February 4, 2025 | bovnews.comBZomedica Corp (ZOM) Stock Trading RecapJanuary 17, 2025 | bovnews.comBNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonMicron’s Big Q3 Drives Applied Materials’ Bullish OutlookBy Leo Miller | July 3, 2025View Micron’s Big Q3 Drives Applied Materials’ Bullish OutlookIgnore the Noise—Samsara Stock Is Still a Strong BuyBy Sam Quirke | June 12, 2025View Ignore the Noise—Samsara Stock Is Still a Strong BuyUber and Tesla Surge on Robotaxis, Analyst Touts Texas RidesBy Leo Miller | June 25, 2025View Uber and Tesla Surge on Robotaxis, Analyst Touts Texas RidesMarketBeat Week in Review – 06/30 - 07/04By MarketBeat Staff | July 5, 2025View MarketBeat Week in Review – 06/30 - 07/04BMK, ZOM, AMYT, FIRE, and HLS Company DescriptionsAmryt Pharma NASDAQ:AMYTAmryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.MacDonald Mines Exploration CVE:BMKC$0.08 -0.01 (-10.53%) As of 05/6/2025MacDonald Mines Exploration Ltd. engages in the acquisition, exploration, and development of mineral properties in Canada. The company primarily explores for gold, silver, copper, cobalt, and nickel deposits. It owns 100% interests in the Scadding-Powerline-Jovan project that covers an area of 19,455 hectares located in the southeast of the prolific Sudbury Mining Camp in Northern Ontario; and the Hembruff Copper Property, which consists of 30 mining claims that covers an area of 6.64 square kilometers situated in the Elliot Lake, Ontario. The company was formerly known as MacDonald Mines Limited. MacDonald Mines Exploration Ltd. was founded in 1935 and is based in Toronto, Canada.(FIRE) NASDAQ:FIRESourcefire, Inc. (Sourcefire) is engaged in the business of delivering intelligent cybersecurity technologies. The Company provides a portfolio of solutions that enables commercial enterprises and government agencies worldwide to manage and minimize cybersecurity risks. Sourcefire provides customers with Agile Security that consists of hardware with embedded software, software and cloud-based solutions. It sells its solutions to a customer base that includes Global 2000 companies, global enterprises, the United States and international government agencies, and small and mid-size businesses. During the year ended December 31, 2012, it generated approximately 67% of the Company's revenue from customers in the United States, and 33% of the Company's revenue from customers outside of the United States. As of December 31, 2012, its product revenue and services revenue represented 61% and 39% of its total revenue, respectively.HLS Therapeutics TSE:HLSC$4.94 +0.04 (+0.82%) As of 07/4/2025 01:54 PM EasternHLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States and the Rest of the world.Zomedica NYSEAMERICAN:ZOMZomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system. It also provides therapeutic products, including PulseVet electrohydraulic shockwave therapy platform; and Assisi Loop line of products, including the Assisi Loop, Assisi Loop Lounge, and DentaLoop devices that treat pain and inflammation through delivery of targeted pulsed electromagnetic field focused energy. The company has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for the development of a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. is headquartered in Ann Arbor, Michigan. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Warehouse Wars: Can BJ’s Take Advantage of Costco’s Weakness? Correction Equals Opportunity in Domino’s Pizza Stock Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story CAVA Group: Why the Growth Story Is Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
